Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Retinal Disease
Interventions: Imaging Session; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Genotype, Retinal Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-Related Macular Degeneration (AMD)
Interventions: PAN-90806 Ophthalmic Solution, Lucentis; Drug
Lead sponsor: PanOptica, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more

Conditions: Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Normal Healthy Subjects With no Known Ocular Diseases
Interventions: Topcon TRC-NW400, TRC-NW8, TRC-NW400, Canon-CR2, Zeiss Visucam PRO; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Oakland, New Jersey

Conditions: Retinoschisis, X-Linked
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: 4D-150 IVT, Aflibercept IVT; Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 17
States / cities: Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more

Conditions: Dry Macular Degeneration
Interventions: Adipose Derived Stem Cells; Biological
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 50 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Sunrise, Florida

Conditions: Retinoblastoma
Interventions: Melphalan, Carboplatin; Drug
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Age Related Macular Degeneration
Interventions: NeoVista Ophthalmic System; Device
Lead sponsor: NeoVista; Industry
Eligibility: 50 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Phoenix, Arizona • Honolulu, Hawaii

Conditions: Choroideremia, X-Linked Retinitis Pigmentosa
Interventions: BIIB111, BIIB112; Genetic
Lead sponsor: NightstaRx Ltd, a Biogen Company; Other
Eligibility: 18 Years and older · Male only
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Open Angle Glaucoma (OAG), Glaucoma
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Wet Macular Degeneration
Interventions: BI 836880; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Placebo, LFG316; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio

Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 4 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Conditions: Post-surgical Cystoid Macular Edema (PSCME)
Interventions: PredA + Kelac; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
Interventions: Metformin hydrochloride; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions: Intravitreal Aflibercept Injection; Drug
Lead sponsor: Ophthalmic Consultants of Boston; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-Related Macular Degeneration
Interventions: Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium); Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Aging, Age-Related Macular Degeneration
Interventions: ZeaVision EyePromise Restore, Multivitamin; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Macular Degeneration
Interventions: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 176
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more

Conditions: Central Retinal Vein Occlusion
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Bakersfield, California • Santa Barbara, California • Santa Maria, California

Conditions: Macular Degeneration
Interventions: EyePromise Visual Edge; Dietary Supplement
Lead sponsor: Robert Davis; Other
Eligibility: 50 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: North Chicago, Illinois • Oak Lawn, Illinois

Search by objective public record fields.

Data Collection With the P200TE and P200TxE

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Retinal Fundus Camera Evaluation

Mothers Experiences With X-linked Retinoschisis Compared to Fathers Experiences

4D-150 in Patients With Diabetic Macular Edema

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration

A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma

A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

Oral Metformin for Treatment of ABCA4 Retinopathy

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Investigation of Macular Pigment Augmentation on Dark Adaptation

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

"Night Vision and Carotenoids"